Shares in Pharming Group NV sank by more than 65 percent on news that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion on a marketing authorization application for its lead drug, the hereditary angioedema treatment Rhucin. (BioWorld International)

Having proven the efficacy of its bone-graft product for the foot and ankle in a Canadian pivotal trial, BioMimetic Therapeutics Inc. is selling rights for the marketed periodontal therapy based on the same platform, thereby gaining $40 million in cash that will be used for other product development. (BioWorld Today)